Summary: Evaluated carvedilol versus metoprolol in patients with systolic heart failure (EF < 35%), New York Heart Association Functional class II-IV symptoms, prior hospitalization for cardiac cause and optimal treatment with diuretics and ACE inhibitors.
The primary endpoint of all-cause mortality was reduced using carvedilol compared to metoprolol (17% reduction). There was no difference in the composite of all-cause mortality plus hospitalization and there was no difference in reported side-effects.
Lancet. 2003 Jul 5;362(9377):7-13.
Eponym: Carvedilol Or Metoprolol European Trial